ProMeris Duo

Withdrawn

This medicine's authorisation has been withdrawn

metaflumizone / amitraz

Overview

The marketing authorisation for ProMeris Duo has been withdrawn at the request of the marketing authorisation holder.

ProMeris Duo : EPAR - Summary for the public

Product information

ProMeris Duo : EPAR - Product Information

ProMeris Duo : EPAR - All Authorised presentations

Product details

• Name of medicine:
  ProMeris Duo
• Active substance:
  • metaflumizone
  • amitraz
• International non-proprietary name (INN) or common name:
  • metaflumizone
  • amitraz
• Species:
  Dogs
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QP53AD51

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), and ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs.

The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Authorisation details

• EMA product number:
  EMEA/V/C/000108
• Marketing authorisation holder:
  Pfizer Limited

  Pfizer Limited; Ramsgate Road; Sandwich; Kent CT13 9NJ; United Kingdom

• Marketing authorisation issued:
  19/12/2006
• Revision:
  7

Assessment history

Changes since initial authorisation of medicine

ProMeris Duo : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

ProMeris Duo : EPAR - Scientific Discussion

ProMeris Duo : EPAR - Procedural steps taken before authorisation